Therapeutic potential of venom peptides

被引：610
作者：
Lewis, RJ [1 ]
Garcia, ML
机构：
[1] Univ Queensland, Inst Mol Biosci, St Lucia, Qld 4072, Australia
[2] Xenome Ltd, Indooroopilly, Qld 4068, Australia
[3] Merck Res Labs, Dept Ion Channels, Rahway, NJ 07065 USA
来源：
NATURE REVIEWS DRUG DISCOVERY | 2003年 / 2卷 / 10期
基金：
澳大利亚研究理事会; 英国医学研究理事会;
关键词：
D O I：
10.1038/nrd1197
中图分类号：
Q81 [生物工程学（生物技术）]; Q93 [微生物学];
学科分类号：
071005 ; 0836 ; 090102 ; 100705 ;
摘要：
Venomous animals have evolved a vast array of peptide toxins for prey capture and defence. These peptides are directed against a wide variety of pharmacological targets, making them an invaluable source of ligands for studying the properties of these targets in different experimental paradigms. A number of these peptides have been used in vivo for proof-of-concept studies, with several having undergone preclinical or clinical development for the treatment of pain, diabetes, multiple sclerosis and cardiovascular diseases. Here we survey the pharmacology of venom peptides and assess their therapeutic prospects.
引用
收藏
页码：790 / 802
页数：13
相关论文
共 142 条
  • [1] ω-conotoxin CVID inhibits a pharmacologically distinct voltage sensitive calcium channel associated with transmitter release from preganglionic nerve terminals
    Adams, DJ
    Smith, AB
    Schroeder, CI
    Yasuda, T
    Lewis, RJ
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 2003, 278 (06) : 4057 - 4062
  • [2] A tetrodotoxin-resistant voltage-gated sodium channel expressed by sensory neurons
    Akopian, AN
    Sivilotti, L
    Wood, JN
    [J]. NATURE, 1996, 379 (6562) : 257 - 262
  • [3] Advances in the pharmacological control of the bladder
    Andersson, KE
    [J]. EXPERIMENTAL PHYSIOLOGY, 1999, 84 (01) : 195 - 213
  • [4] Molecular determinants by which a long chain toxin from snake venom interacts with the neuronal α7-nicotinic acetylcholine receptor
    Antil-Delbeke, S
    Gaillard, C
    Tamiya, T
    Corringer, PJ
    Changeux, JP
    Servent, D
    Ménez, A
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 2000, 275 (38) : 29594 - 29601
  • [5] BADIO B, 1994, MOL PHARMACOL, V45, P563
  • [6] Broad-spectrum, non-opioid analgesic activity by selective modulation of neuronal nicotinic acetylcholine receptors
    Bannon, AW
    Decker, MW
    Holladay, MW
    Curzon, P
    Donnelly-Roberts, D
    Puttfarcken, PS
    Bitner, RS
    Diaz, A
    Dickenson, AH
    Porsolt, RD
    Williams, M
    Arneric, SP
    [J]. SCIENCE, 1998, 279 (5347) : 77 - 81
  • [7] A novel fluorescent toxin to detect and investigate Kv1.3 channel up-regulation in chronically activated T lymphocytes
    Beeton, C
    Wulff, H
    Singh, S
    Botsko, S
    Crossley, G
    Gutman, GA
    Cahalan, MD
    Pennington, M
    Chandy, KG
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 2003, 278 (11) : 9928 - 9937
  • [8] Selective blockade of T lymphocyte K+ channels ameliorates experimental autoimmune encephalomyelitis, a model for multiple sclerosis
    Beeton, C
    Wulff, H
    Barbaria, J
    Clot-Faybesse, O
    Pennington, M
    Bernard, D
    Cahalan, MD
    Chandy, KG
    Béraud, E
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2001, 98 (24) : 13942 - 13947
  • [9] Defibrinogenating enzymes
    Bell, WR
    [J]. DRUGS, 1997, 54 (Suppl 3) : 18 - 30
  • [10] Novel platelet inhibitors
    Bennett, JS
    [J]. ANNUAL REVIEW OF MEDICINE, 2001, 52 : 161 - 184
12345678910